Caris & Co Upgrades Par Pharmaceutical (PRX) to Buy
Tweet Send to a Friend
Caris & Co upgrades Par Pharmaceutical (NYSE: PRX) from Above Average to Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE